[
  {
    "ts": null,
    "headline": "Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick.",
    "summary": "Unlike the broad reciprocal tariffs announced on April 2, which triggered a market crash, Trump’s new drug tariffs, announced in conjunction with a new government-run drug sales platform last month, seems to have boosted investor confidence.  Stocks of major pharmaceutical firms, including  Eli Lilly GSK Merck Novartis Johnson & Johnson  and  Pfizer rose.  The market’s reaction suggests enthusiasm for the administration’s multifaceted strategy to overhaul the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=fde8b62877dcbe4bf2b03b87a111b78c324445ab22863a4ab7e9d31e5ca48347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759949280,
      "headline": "Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick.",
      "id": 137028255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Unlike the broad reciprocal tariffs announced on April 2, which triggered a market crash, Trump’s new drug tariffs, announced in conjunction with a new government-run drug sales platform last month, seems to have boosted investor confidence.  Stocks of major pharmaceutical firms, including  Eli Lilly GSK Merck Novartis Johnson & Johnson  and  Pfizer rose.  The market’s reaction suggests enthusiasm for the administration’s multifaceted strategy to overhaul the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=fde8b62877dcbe4bf2b03b87a111b78c324445ab22863a4ab7e9d31e5ca48347"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says",
    "summary": "Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics (",
    "url": "https://finnhub.io/api/news?id=c302e5b61bd685ba464983de1216de8b164e4229bb67f1b2ccabe44038474cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759949139,
      "headline": "Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says",
      "id": 137012895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics (",
      "url": "https://finnhub.io/api/news?id=c302e5b61bd685ba464983de1216de8b164e4229bb67f1b2ccabe44038474cd8"
    }
  },
  {
    "ts": null,
    "headline": "Why The Narrative Around J&J Is Shifting Amid Analyst Upgrades and Pharma Developments",
    "summary": "Johnson & Johnson stock has recently seen its consensus analyst price target lifted from $179.64 to $185.13, marking an increase of approximately $5.49 as market sentiment improves. This upward revision comes as analysts anticipate renewed growth and express confidence in Johnson & Johnson's strategic direction, following noteworthy developments in its Pharma segment. Stay tuned to discover how you can stay informed and ahead as the story surrounding Johnson & Johnson's evolving narrative...",
    "url": "https://finnhub.io/api/news?id=bfe65b4ac0d8a8cadb5f78429819837869dad9321f8b069211fecca762a91b1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759943683,
      "headline": "Why The Narrative Around J&J Is Shifting Amid Analyst Upgrades and Pharma Developments",
      "id": 137012896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson stock has recently seen its consensus analyst price target lifted from $179.64 to $185.13, marking an increase of approximately $5.49 as market sentiment improves. This upward revision comes as analysts anticipate renewed growth and express confidence in Johnson & Johnson's strategic direction, following noteworthy developments in its Pharma segment. Stay tuned to discover how you can stay informed and ahead as the story surrounding Johnson & Johnson's evolving narrative...",
      "url": "https://finnhub.io/api/news?id=bfe65b4ac0d8a8cadb5f78429819837869dad9321f8b069211fecca762a91b1e"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again",
    "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=cce9e17dcabb116791206efcff93ccd91af8a25d455e002aad7412c989be9650",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759939802,
      "headline": "Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again",
      "id": 137012897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=cce9e17dcabb116791206efcff93ccd91af8a25d455e002aad7412c989be9650"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease",
    "summary": "BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.",
    "url": "https://finnhub.io/api/news?id=f74d2ae582a28408223a0a5398e1b995b1a398278e9126f9f63d12a14aa49d64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759936980,
      "headline": "Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease",
      "id": 137012898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.",
      "url": "https://finnhub.io/api/news?id=f74d2ae582a28408223a0a5398e1b995b1a398278e9126f9f63d12a14aa49d64"
    }
  },
  {
    "ts": null,
    "headline": "Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?",
    "summary": "HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.",
    "url": "https://finnhub.io/api/news?id=a3e6696de7c2dd6fce9991c9f6f94ac684b1ff884e0feb310fa4aaba6b00d37f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759934940,
      "headline": "Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?",
      "id": 137012899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.",
      "url": "https://finnhub.io/api/news?id=a3e6696de7c2dd6fce9991c9f6f94ac684b1ff884e0feb310fa4aaba6b00d37f"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=afdfaba6b7c51f1133a96464887e4db4662f02821dec1f7acb6572d26322dd3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759928403,
      "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
      "id": 137010910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=afdfaba6b7c51f1133a96464887e4db4662f02821dec1f7acb6572d26322dd3c"
    }
  },
  {
    "ts": null,
    "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
    "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
    "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927320,
      "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
      "id": 137010911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Season Is Starting. Can Strong Profits Keep the Stock Market Rally Going?",
    "summary": "Third-quarter profit growth should be solid. Tech and AI will lead the way, but earnings momentum could broaden too.",
    "url": "https://finnhub.io/api/news?id=f121231249e2180c2c02cf964ee7058b5c3e6266bfce6ed461fd31a739c878c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759925640,
      "headline": "Earnings Season Is Starting. Can Strong Profits Keep the Stock Market Rally Going?",
      "id": 137010855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third-quarter profit growth should be solid. Tech and AI will lead the way, but earnings momentum could broaden too.",
      "url": "https://finnhub.io/api/news?id=f121231249e2180c2c02cf964ee7058b5c3e6266bfce6ed461fd31a739c878c9"
    }
  },
  {
    "ts": null,
    "headline": "Medtech M&A has remained slow this year. But 2 execs are ready to make a deal",
    "summary": "Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.",
    "url": "https://finnhub.io/api/news?id=a6273c316611d36fae2d2a71718defd2409f4814b6e597a31e45f903f2701b51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759916933,
      "headline": "Medtech M&A has remained slow this year. But 2 execs are ready to make a deal",
      "id": 137010913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.",
      "url": "https://finnhub.io/api/news?id=a6273c316611d36fae2d2a71718defd2409f4814b6e597a31e45f903f2701b51"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into […]",
    "url": "https://finnhub.io/api/news?id=ac153d28000ac47d8816c6e3b5b48fe2a2d6a54e5665dda2fc8ca0c7019546ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759902222,
      "headline": "Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks",
      "id": 137007973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of America’s most recognizable healthcare companies, with operations that now center on pharmaceuticals and medical devices. After spinning off its consumer health unit, which included familiar names like Tylenol, Neutrogena, and Listerine, into […]",
      "url": "https://finnhub.io/api/news?id=ac153d28000ac47d8816c6e3b5b48fe2a2d6a54e5665dda2fc8ca0c7019546ab"
    }
  },
  {
    "ts": null,
    "headline": "Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio",
    "summary": "These two market leaders have increased their dividends for a combined 115 years.",
    "url": "https://finnhub.io/api/news?id=368b44d9d5ce7f9511d459b01394d1d88ca78b5efefe599a6f7c291f7c46b18a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759885080,
      "headline": "Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio",
      "id": 137007974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "These two market leaders have increased their dividends for a combined 115 years.",
      "url": "https://finnhub.io/api/news?id=368b44d9d5ce7f9511d459b01394d1d88ca78b5efefe599a6f7c291f7c46b18a"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "summary": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=d73f6c4faa14cb50c1001acfe04846bebf73109be78e78e9af0a8800b0e1f8dd",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759881937,
      "headline": "Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation",
      "id": 137005018,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d73f6c4faa14cb50c1001acfe04846bebf73109be78e78e9af0a8800b0e1f8dd"
    }
  }
]